AVROBIO Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
TECX$21.97+0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss)
(amounts in thousands, except per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $47,700 | $72,186 |
| General and administrative | 23,967 | 33,248 |
| Total operating expenses | 71,667 | 105,434 |
| Gain on asset sale | 83,736 | — |
| Loss on impairment | (1,877) | — |
| Income (loss) from operations | 10,192 | (105,434) |
| Other income (expense): | ||
| Interest income (expense), net | 2,420 | (299) |
| Other expense, net | (78) | (157) |
| Total other income (expense), net | 2,342 | (456) |
| Income (loss) before income taxes | 12,534 | (105,890) |
| Provision for income tax expense | 377 | — |
| Net income (loss) and comprehensive income (loss) attributable to common stockholders—basic and diluted | $12,157 | $(105,890) |
| Earnings per share: | ||
| Net income (loss) per share applicable to common stockholders—basic | $0.27 | $(2.42) |
| Net income (loss) per share applicable to common stockholders—diluted | $0.27 | $(2.42) |
| Shares used in computing earnings per share: | ||
| Weighted-average common shares outstanding—basic | 44,327 | 43,739 |
| Weighted-average common shares outstanding—diluted | 44,568 | 43,739 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.